Search - tctmd.com

Displaying 1 - 20 of 71

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

Caitlin E. Cox

June 25, 2025

News Daily News

Amylin Analogue Boosts Weight Loss When Added to GLP-1

L.A. McKeown

June 24, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Yael L. Maxwell

November 16, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

Todd Neale

December 22, 2023

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

Shelley Wood

December 19, 2023

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

News Opinion CV Team Dispatch

June 2023 News Roundup

L.A. McKeown

June 01, 2023

Advertisement

Year in Review: Top Prevention Stories of 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

Amylin Analogue Boosts Weight Loss When Added to GLP-1

April 2025 Dispatch for the CV Team

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

November 2024 Dispatch for the CV Team

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

AHA Selects 2023’s Leading Cardiovascular Research

Who Benefits Most From Semaglutide and How Long Will That Take?

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

June 2023 News Roundup

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content